Evidence map›Paper›PMID 24828054›Full record

ReviewTissue antigens2014

MHC class I signaling: new functional perspectives for an old molecule.

E W Tsai, E F Reed

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Tissue antigens, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Divide, Conquer, and Sense: CD8Frontiers in immunology · 2016
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

E W TsaiMattel Children's Hospital UCLA, Division of Pediatric Nephrology, Los Angeles, CA, USA.
E F Reed
Boston Children's Hospital · USUniversity of California, Los Angeles · US

Funding

Development of Transplant Strategies Uniquely Responsive to the Needs of ChildrenU01AI077821 · NIAID · EMORY UNIVERSITY · PI KIRK, ALLAN D. · 2008 to 2012
$7.5M
Anti-MHC Effects on EndotheliumR01AI042819 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI REED, ELAINE F · 1999 to 2014
$4.0M
Anti-HLA Antibody Activation of Endothelial Cells in Cardiac TransplantationR01HL090995 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI REED, ELAINE F · 2008 to 2010
$1.2M
Anti-MHC Effects on EndotheliumR56AI042819 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI REED, ELAINE F · 2015 to 2015
$385k
NHLBI NIH HHS R01 HL 090995NHLBI NIH HHS R01 HL090995NIAID NIH HHS R01 AI 042819NIAID NIH HHS R01 AI042819NIAID NIH HHS R56 AI042819NIAID NIH HHS U01 AI077821NIAID NIH HHS U01AI077821
6 · The paper itself

Abstract

Donor-specific antibodies are associated with refractory rejection episodes and poor allograft outcomes in solid organ transplantation. Our understanding of antibody-mediated allograft injury is expanding beyond complement deposition. In fact, unique mechanisms of alloantibodies are advancing our knowledge about transplant vasculopathy and antibody-mediated rejection. These include direct effects on the endothelium, resulting in the recruitment of leukocytes, chemokine and cytokine production, and stimulation of innate and adaptive alloresponses. These effects will be the focus of the following review.

Indexed as

AnimalsArteriosclerosisCell ProliferationCytokinesEndothelium, VascularGraft RejectionHistocompatibility Antigens Class IHumansImmunosuppressive AgentsIsoantibodiesMuscle, Smooth, VascularProtein Kinase InhibitorsSignal TransductionCytokinesHistocompatibility Antigens Class IImmunosuppressive AgentsIsoantibodiesProtein Kinase Inhibitorsalloantibodiesantibody-mediated rejectioncomplementendotheliumhuman leukocyte antigen class Itherapytransplant vasculopathy

Identifiers

PMID24828054
PMCPMC4079505
OpenAlexW1938598055

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.